Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

TransMedics (TMDX) Gains from Sales and Divestitures (2024 - 2025)

TransMedics has reported Gains from Sales and Divestitures over the past 2 years, most recently at $1280.0 for Q4 2025.

For Q4 2025, Gains from Sales and Divestitures rose 113.33% year-over-year to $1280.0; the TTM value through Dec 2025 reached $1280.0, up 113.33%, while the annual FY2025 figure was $1280.0, 113.33% up from the prior year.
Gains from Sales and Divestitures for Q4 2025 was $1280.0 at TransMedics, down from $15157.0 in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $111419.0 in Q1 2025 and troughed at -$9606.0 in Q4 2024.